In a recent Gallup poll, pain, anxiety, arthritis, and insomnia were among the top causes of using cannabidiol for the participants. Anyhow, the US FDA still does not approve any CBD pain relief product.
As the federal agency keeps gathering evidence about CBD product use and effectiveness, users and marketers claim that the items have various advantages, including pain relief. The new Syracuse University research may be able to support such claims. Featured in the Experimental and Clinical Psychopharmacology journal, the research provides new insights into cannabidiol’s capability of reducing pain, plus the placebo effect’s possible influence on pain results.
One of this study’s researchers, namely Martin De Vita, wondered whether the pain reduction that CBD consumers claim to have is because of placebo or pharmacological effects. She said that it is a fair consideration because even telling somebody that a particular substance can reduce their pain possibly changes their sensitivity. Those are known as expectancy effects.
Complex, But Fascinating Study Findings
The information showed that cannabidiol and the expectations of people from it do not seem to make experimental pain less intense, but it causes the pain to be less unpleasant.
The researchers hypothesized that the so-called ‘placebo analgesia’ effect that occurs due to the expectations are mainly detectable. After measuring many different pain results, the researchers discovered a mixed bag of things. To be precise, they discovered that pain measures got better because of cannabidiol’s pharmacological effects as well as the effects of thinking that the participants received cannabidiol. The researchers concerned concluded that there is a need for future studies of the pharmacological and psychological mechanisms that underlie CBD analgesia.
The data may be exciting, but it is complex because various pain measures reacted in different ways to the expectation and/or the substance’s effect. The researchers are still attempting to determine why the differential information exists with different pain measure types. Their next step would be to study the mechanisms that underlie those findings as well as determine why offering cannabidiol or instructions causes certain responses to pain stimuli.
This was not the first time that Gallup conducted a poll on CBD dosage for pain, and it may not be the last time either. Gallup has access to such a large CBD customer base that it could come up with those surveys and help researchers with useful insights.